Appili Therapeutics Inc. (OTCMKTS:APLIF) Short Interest Update

Appili Therapeutics Inc. (OTCMKTS:APLIF) saw a significant decline in short interest in the month of January. As of January 15th, there was short interest totalling 13,800 shares, a decline of 55.9% from the December 31st total of 31,300 shares. Based on an average daily volume of 40,400 shares, the short-interest ratio is presently 0.3 days.

Appili Therapeutics Trading Down 2.5 %

Shares of Appili Therapeutics stock traded down $0.00 on Thursday, reaching $0.02. 22,035 shares of the company were exchanged, compared to its average volume of 32,658. The stock has a fifty day moving average price of $0.03 and a 200-day moving average price of $0.03. The firm has a market capitalization of $2.81 million, a price-to-earnings ratio of -1.16 and a beta of -0.52. Appili Therapeutics has a fifty-two week low of $0.01 and a fifty-two week high of $0.05.

About Appili Therapeutics

Appili Therapeutics Inc, a biopharmaceutical company, focuses on the acquisition and development of novel medicines for unmet needs in infectious disease in Canada. Its anti-infective portfolio includes ATI-1501, a taste-masked liquid oral suspension formulation of the antibiotic metronidazole to treat anaerobic bacterial, protozoal, and parasitic infections; ATI-1801, a novel topical formulation of paromomycin in Phase III clinical trials for the treatment of cutaneous leishmaniasis and disfiguring skin infections; and ATI-1701, which is a live-attenuated vaccine in preclinical trials for Francisella tularensis.